GLP-1 + Allergy Immunotherapy and Antihistamines

Allergic rhinitis affects roughly one in five US adults (Wise 2023, the ICAR-AR synopsis^[1]), and the treatment ladder spans cheap over-the-counter antihistamines all the way to $30,000-a-year biologics. The honest answer for anyone on Wegovy, Zepbound, Ozempic, Mounjaro, or compounded semaglutide is that none of the allergy medications — not loratadine, not fluticasone nasal spray, not sublingual immunotherapy, not dupilumab, not tezepelumab — have a clinically meaningful pharmacokinetic interaction with GLP-1 receptor agonists or with tirzepatide. The largest review of GLP-1 drug-drug interactions to date (Min 2025, Drug Design Development and Therapy^[9]) covers most therapeutic classes; the practical interaction concerns are limited to narrow-therapeutic-index orals and time-of-day dosing, neither of which apply to allergy treatment. This article walks through what is and is not a real concern.

The honest summary

• Second-generation oral antihistamines are compatible. Loratadine (Claritin), cetirizine (Zyrtec), and fexofenadine (Allegra) have no clinically meaningful interaction with GLP-1 receptor agonists. A modest delay in oral absorption from gastric slowing is possible (Min 2025^[9]) but does not change 24-hour symptom control. Take them at the same time you would otherwise.
• Intranasal steroids act locally. Fluticasone (Flonase), mometasone (Nasonex), and combination azelastine-fluticasone (Dymista) are absorbed minimally into the systemic circulation. There is no GLP-1 interaction to discuss.
• Sublingual immunotherapy works as labeled. The timothy-grass and ragweed SLIT tablets (Grastek, Oralair, Ragwitek) act locally on oral mucosal dendritic cells (Dahl 2006^[4], Kim 2014^[5]). A GLP-1 does not slow that local immune mechanism.
• Biologics for severe disease are unaffected. Omalizumab (Xolair, anti-IgE), dupilumab (Dupixent, anti-IL-4 / IL-13^[2]), and tezepelumab (Tezspire, anti-TSLP^[3]) are subcutaneous large-molecule therapies cleared by the reticuloendothelial system — no hepatic metabolism, no gastric-emptying step, no interaction with a GLP-1 receptor agonist.

How big a problem is allergic rhinitis in the GLP-1 population?

The 2023 International Consensus on Allergic Rhinitis synopsis (Wise 2023^[1]) estimates the US adult prevalence at roughly 20% — meaning a typical telehealth GLP-1 panel of 1,000 patients will include 150 to 250 with clinically significant nasal symptoms during peak pollen seasons. The clinical concern is not that the GLP-1 worsens the allergy. It is the reverse: patients already on a long list of medications for AR sometimes assume that adding a GLP-1 will require stopping or rotating the AR regimen. With the partial exception of montelukast (discussed below), the evidence does not support that worry.

Oral antihistamines and the gastric-emptying question

Second-generation H1 antihistamines — loratadine, cetirizine, fexofenadine, levocetirizine, desloratadine — are absorbed in the small intestine and have plasma half-lives in the 10–28 hour range. The systematic review of second-gen antihistamine pharmacokinetic interactions (Paśko 2017, Biomedicine & Pharmacotherapy^[6]) examined dietary and ethanol effects and did not identify any clinically meaningful loss of efficacy from delayed absorption. The GLP-1 receptor agonist class slows gastric emptying — semaglutide modestly, tirzepatide more so — and Min 2025^[9] documents how that slowing affects narrow-therapeutic-index oral drugs (warfarin, oral contraceptives at initiation, levothyroxine timing). Allergy antihistamines are not narrow-therapeutic-index; a 15–45 minute delay in time-to-peak does not change daily symptom control. The practical advice is to take the antihistamine at the same time each day, not necessarily with food, and to use a once-daily formulation if you are on a higher tirzepatide dose where transit may be the slowest.

First-generation antihistamines — diphenhydramine (Benadryl), chlorpheniramine, hydroxyzine — are no longer first-line for allergic rhinitis because of the sedation and anticholinergic burden. If you do take one for occasional severe symptoms or for sleep, the GLP-1 does not change the sedation profile.

Intranasal steroids: no systemic exposure to worry about

Fluticasone propionate (Flonase), fluticasone furoate (Flonase Sensimist), mometasone (Nasonex), triamcinolone (Nasacort), and budesonide (Rhinocort) are delivered as topical sprays. Systemic bioavailability is below 1% for fluticasone furoate and below 8% for the older fluticasone propionate (Wise 2023^[1] reviews the class). The combination azelastine-fluticasone product (Dymista) has the same local-action profile. There is no published GLP-1 interaction with this class because the pharmacokinetic surface that a GLP-1 can act on — gastric emptying, oral absorption — is bypassed entirely.

Montelukast: a non-GLP-1 caveat worth flagging

Montelukast (Singulair) is a leukotriene receptor antagonist with a 2020 FDA black-box warning for neuropsychiatric events including agitation, depression, and suicidal ideation. The sequence symmetry analysis of pharmacy claims (Fox 2022, Journal of Asthma^[7]) confirmed a small but real association with antidepressant initiation in the months following montelukast prescription. This is independent of GLP-1 therapy; the recent post-hoc psychiatric-safety analysis of the STEP semaglutide trials (Wadden 2024 JAMA Internal Medicine^[8]) reported no increase in depression or suicidal-ideation signals attributable to semaglutide. Translation: if you are on montelukast and a GLP-1 and you are experiencing new mood symptoms, the most likely culprit per the published evidence is montelukast, not the GLP-1. Discuss with the prescriber whether the montelukast is still earning its place — for most allergic rhinitis patients, an intranasal steroid plus an oral second-generation antihistamine outperforms montelukast and avoids the psychiatric signal.

Sublingual immunotherapy (SLIT): local action, no GLP-1 effect

The three FDA-approved SLIT tablets target the three highest- prevalence US allergens: timothy-grass (Grastek), five-grass (Oralair), and short ragweed (Ragwitek). The pivotal randomized trials for grass SLIT (Dahl 2006, Allergy^[4]) and ragweed SLIT (Kim 2014, Allergy Asthma and Clinical Immunology^[5]) established the symptom-score and medication-use reductions that remain the label-supporting evidence today. The mechanism is local antigen presentation at oral-mucosal Langerhans cells and downstream T-regulatory cell induction. The tablets are held sublingually for one minute and then swallowed; food and drink are restricted for the next five minutes. A GLP-1 receptor agonist does not interrupt the local immune induction step. The first dose is given in a clinician's office because of a small anaphylaxis risk; the GLP-1 does not modify that risk profile.

Subcutaneous immunotherapy (SCIT, the “allergy shots” pathway) is delivered into subcutaneous tissue on a weekly-then-monthly cadence over three to five years. There is no shared pharmacokinetic surface with a GLP-1. Patients can continue their build-up and maintenance schedule without modification while initiating or up-titrating Wegovy, Zepbound, Mounjaro, or Ozempic.

The biologics tier: anti-IgE, anti-IL-4/13, anti-TSLP

For patients with severe allergic disease, chronic rhinosinusitis with nasal polyps, or severe asthma with nasal involvement, the biologic options are anti-IgE (omalizumab / Xolair), anti-IL-4 receptor alpha (dupilumab / Dupixent), and anti-TSLP (tezepelumab / Tezspire). All three are administered subcutaneously and cleared by the reticuloendothelial system rather than hepatic CYP enzymes. None has a GLP-1 interaction.

Dupilumab in chronic rhinosinusitis with nasal polyps was established by LIBERTY NP SINUS-24 and SINUS-52 (Bachert 2019, Lancet^[2]). Both trials showed roughly −2-point reductions in nasal polyp score and 60%+ improvements in nasal congestion and smell-loss endpoints over 24–52 weeks. The injection cadence is every two weeks at home; the GLP-1 schedule is weekly subcutaneous — the two injections can coexist on the same day or on different days, prescriber preference.

Tezepelumab in severe uncontrolled asthma was established by NAVIGATOR (Menzies-Gow 2021, NEJM^[3]), which showed a 56% reduction in annualized exacerbation rate over 52 weeks regardless of baseline eosinophil status. NAVIGATOR enrolled patients with comorbid allergic rhinitis at high rates and the nasal-symptom secondary endpoints improved consistently. There is no published interaction with GLP-1 therapy.

Omalizumab (anti-IgE) is approved for chronic spontaneous urticaria and severe allergic asthma, with off-label use in severe perennial allergic rhinitis unresponsive to intranasal steroid plus second-gen antihistamine. Subcutaneous dosing is every two to four weeks based on serum IgE and body weight. No GLP-1 interaction. Anaphylaxis risk with the first dose is well characterized at the population level (roughly 1 in 1,000) and is not modified by concurrent GLP-1 therapy.

EpiPen, anaphylaxis, and GLP-1 weight loss

Patients with documented anaphylaxis to insect stings, foods, or biologics should continue to carry an epinephrine auto-injector (EpiPen, Auvi-Q) while on a GLP-1. The intramuscular epinephrine dose is unchanged. Weight loss does not alter the standard 0.3 mg adult dose recommended by the American College of Allergy, Asthma and Immunology. If body weight drops into the pediatric-dose range under 30 kg, that is a separate consideration that does not apply to adult GLP-1 patients.

Magnitude: symptom score change at 12 weeks by intervention

Insurance and cost in 2026

The second-generation oral antihistamines are all over-the-counter and run roughly $10–20 per month at retail, less at warehouse-club pricing. Intranasal steroids are similarly OTC at $15–30 per month for fluticasone or mometasone. SLIT tablets typically run $300–500 per month and are covered by most commercial insurance plans with prior authorization. The biologic tier (omalizumab, dupilumab, tezepelumab) carries list prices in the $30,000–50,000 per year range and is normally accessed through a specialty pharmacy with manufacturer co-pay support. None of these reimbursement pathways are affected by concurrent GLP-1 therapy.

The practical protocol

1. Continue your current allergy regimen when starting a GLP-1. Do not stop intranasal steroids, SLIT tablets, or SCIT shots. Re-time oral antihistamines only if you notice reduced control on a higher tirzepatide dose.
2. Use intranasal steroid first-line for persistent symptoms. The class outperforms oral antihistamines for nasal congestion and has no GLP-1 interaction (Wise 2023^[1]).
3. Reconsider montelukast if you have any history of depression, anxiety, or mood symptoms. The black-box neuropsychiatric warning is independent of GLP-1 use and most patients do well on intranasal steroid plus second-gen antihistamine instead (Fox 2022^[7]).
4. Continue SLIT and SCIT schedules unchanged. The mechanism is local at the oral mucosa or subcutaneous tissue; no GLP-1 interaction is plausible.
5. Maintain biologic dosing on the same calendar. Dupilumab every two weeks, omalizumab every two to four weeks, tezepelumab every four weeks — the GLP-1 weekly injection slots in alongside. Co-administration on the same day is fine; alternate injection sites by 5 cm.
6. Carry epinephrine if you have a documented anaphylaxis history. Adult intramuscular dose (0.3 mg) is unchanged by GLP-1 weight loss.

Related research and tools

• GLP-1 and asthma / COPD lung function — respiratory comorbidity and how the biologics tier overlaps with allergic disease
• GLP-1 with psoriasis and eczema biologics — the parallel anti-IL-23 / TNF / IL-4 biologic compatibility analysis
• GLP-1 first 30 days survival guide — what to expect on titration, including how to schedule concurrent specialty medications
• GLP-1 side effect timeline — week-by-week tolerability map

Important disclaimer. This article is educational and does not constitute medical advice. Decisions about starting, stopping, or adjusting allergy medications, immunotherapy, or biologics should be made with a board- certified allergist or immunologist. Patients with a history of anaphylaxis should continue to carry epinephrine and follow their action plan. Cost figures reflect 2026 US retail and specialty-pharmacy pricing and may change. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if a new biologic is approved for chronic rhinosinusitis or perennial allergic rhinitis with a GLP-1-relevant pharmacokinetic profile.